Meiragtx Holdings Plc (MGTX) - News Archive

In an extraordinary breakthrough in the field of genetic medicine, MeiraGTx Holdings plc (Nasdaq: MGTX), a leading clinical-stage genetic medicines company, has announced the publication of a significant study in The La...

Positive Results from Phase 1 AQUAx Study Bring Hope for Patients with Radiation-Induced XerostomiaRadiation therapy is a common treatment for head and neck cancers, but it often comes with side effects such as radiatio...

In a significant development for MeiraGTx, the company is set to receive a $50 million milestone payment after initiating the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-ve...

MeiraGTx Announces $415 Million Asset Purchase Agreement for X-linked Retinitis Pigmentosa TreatmentMeiraGTx Holdings Plc, a leading gene therapy company, has recently entered into an Asset Purchase Agreement related to...